Johnson & Johnson Free Cash Flow 2012-2026 | JNJ
Johnson & Johnson annual/quarterly free cash flow history and growth rate from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Johnson & Johnson free cash flow for the quarter ending March 31, 2026 was 20,418.00, a year-over-year.
- Johnson & Johnson free cash flow for the twelve months ending March 31, 2026 was , a year-over-year.
- Johnson & Johnson annual free cash flow for 2025 was $20.418B, a 0.48% decline from 2024.
- Johnson & Johnson annual free cash flow for 2024 was $20.517B, a 10.27% increase from 2023.
- Johnson & Johnson annual free cash flow for 2023 was $18.606B, a 4.95% increase from 2022.
| Johnson & Johnson Annual Free Cash Flow | |
|---|---|
| 2025 | 20,418.00 |
| 2024 | 20,517.00 |
| 2023 | 18,606.00 |
| 2022 | 17,728.00 |
| 2021 | 20,469.00 |
| 2020 | 20,494.00 |
| 2019 | 23,183.00 |
| 2018 | 21,734.00 |
| 2017 | 19,609.00 |
| 2016 | 16,808.00 |
| 2015 | 19,570.00 |
| 2014 | 19,627.00 |
| 2013 | 14,277.00 |
| 2012 | 13,971.00 |
| 2011 | 12,747.00 |
| Johnson & Johnson Quarterly Free Cash Flow | |
|---|---|
| 2025-12-31 | 20,418.00 |
| 2025-09-30 | 14,634.00 |
| 2025-06-30 | 6,546.00 |
| 2025-03-31 | 3,658.00 |
| 2024-12-31 | 20,517.00 |
| 2024-09-30 | 15,094.00 |
| 2024-06-30 | 8,080.00 |
| 2024-03-31 | 3,060.00 |
| 2023-12-31 | 18,606.00 |
| 2023-09-30 | 12,211.00 |
| 2023-06-30 | 5,568.00 |
| 2023-03-31 | 2,434.00 |
| 2022-12-31 | 17,728.00 |
| 2022-09-30 | 13,744.00 |
| 2022-06-30 | 8,404.00 |
| 2022-03-31 | 3,620.00 |
| 2021-12-31 | 20,469.00 |
| 2021-09-30 | 16,107.00 |
| 2021-06-30 | 8,552.00 |
| 2021-03-31 | 4,000.00 |
| 2020-12-31 | 20,494.00 |
| 2020-09-30 | 13,269.00 |
| 2020-06-30 | 5,610.00 |
| 2020-03-31 | 2,750.00 |
| 2019-12-31 | 23,183.00 |
| 2019-09-30 | 17,883.00 |
| 2019-06-30 | 11,016.00 |
| 2019-03-31 | 3,140.00 |
| 2018-12-31 | 21,734.00 |
| 2018-09-30 | 14,500.00 |
| 2018-06-30 | 9,022.00 |
| 2018-03-31 | 2,968.00 |
| 2017-12-31 | 19,609.00 |
| 2017-09-30 | 13,638.00 |
| 2017-06-30 | 7,561.00 |
| 2017-03-31 | 2,384.00 |
| 2016-12-31 | 16,808.00 |
| 2016-09-30 | 10,854.00 |
| 2016-06-30 | 6,042.00 |
| 2016-03-31 | 1,575.00 |
| 2015-12-31 | 19,570.00 |
| 2015-09-30 | 14,007.00 |
| 2015-06-30 | 8,229.00 |
| 2015-03-31 | 2,439.00 |
| 2014-12-31 | 19,627.00 |
| 2014-09-30 | 16,369.00 |
| 2014-06-30 | 8,558.00 |
| 2014-03-31 | 3,328.00 |
| 2013-12-31 | 14,277.00 |
| 2013-09-30 | 11,301.00 |
| 2013-06-30 | 6,118.00 |
| 2013-03-31 | 1,797.00 |
| 2012-12-31 | 13,971.00 |
| 2012-09-30 | 11,143.00 |
| 2012-06-30 | 6,630.00 |
| 2012-03-31 | 2,651.00 |
| 2011-12-31 | 12,747.00 |
| 2011-09-30 | 9,803.00 |
| 2011-06-30 | 5,314.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |